CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Anifrolumab (Saphnelo) — Coverage Criteria for Systemic Lupus Erythematosus

Policy governing prior authorization, coverage criteria, documentation, and continuation requirements for Saphnelo (anifrolumab) for adults with moderate to severe systemic lupus erythematosus (SLE) receiving standard therapy under BlueCross BlueShield of Tennessee.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyAnifrolumab (Saphnelo) — Coverage Criteria for SLE

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization with documentation of SLE-relevant autoantibodies (e.g., ANA by IFA ≥1:80) and evidence of standard SLE therapy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsauthorization period

18+member age

severe LN/CNSexclusions

specialistprescriber

Coverage Criteria for Saphnelo (anifrolumab)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

ALL of the following

Member is 18 years of age or older.>= 18 years
Diagnosis of active systemic lupus erythematosus (SLE).
Member is receiving a standard treatment for SLE with one or more of the following (alone or in combination): glucocorticoids (e.g., prednisone, methylprednisolone, dexamethasone), antimalarials (e.g., hydroxychloroquine), or immunosuppressants (e.g., azathioprine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide).
Prior to initiating therapy, the member is positive for autoantibodies relevant to SLE (e.g., ANA by IFA >= 1:80, anti-ds DNA, anti-Sm, antiphospholipid antibodies, or low complement proteins).
Provide laboratory reports or chart documentation.
Medication is prescribed by or in consultation with a rheumatologist or a specialist in the treatment of SLE.
Document specialist involvement in medical record.
Submission of medical records to support the request (e.g., chart notes, laboratory reports) is provided with the prior authorization request.
See documentation requirements for initial requests.

Continuation therapy — criteria for reauthorization

Covered when ALL of the following are met:

ALL of the following

Request is for continuation/re‑authorization of Saphnelo for an indication listed in the coverage criteria.
Member has achieved or maintained a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of SLE.
Provide recent clinical notes and/or disease activity assessments.
Medical records documenting disease stability or improvement are submitted with the continuation request.
Authorization of up to 12 months may be granted for continued treatment when the above criteria are satisfied.

Exclusions: Coverage will not be provided for members with severe active lupus nephritis or severe active central nervous system (CNS) lupus (including seizures attributed to CNS lupus, psychosis, organic brain syndrome, cerebritis, or CNS vasculitis requiring therapeutic intervention) when initiating Saphnelo. Saphnelo should not be used in combination with other biologic therapies. Limitations of use: the efficacy of Saphnelo has not been evaluated in patients with severe active lupus nephritis or severe active CNS lupus; use is not recommended in these situations.

All other indications beyond active SLE are considered experimental/investigational and not medically necessary.

Coding and Laboratory Tests

Required laboratory documentation (tests referenced)mixed

N/A	Documented autoantibody test results required (e.g., antinuclear antibodies [ANA] by immunofluorescence [IFA] 1:80 or higher, anti-doublestranded DNA [anti-dsDNA], anti-Smith [anti-Sm], antiphospholipid antibodies, low complement proteins)

inv-06: ANA titer — threshold

TestANA by immunofluorescence (IFA) titer of 1:80 or higher is required/documented

Test typeAntinuclear antibody (ANA) measured by IFA

ContextRequired as part of initial prior authorization documentation showing SLE‑relevant autoantibodies

Provider Requirements and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior Authorization Required: Prior authorization is required for Saphnelo (anifrolumab) prior to initiation. Authorization may be granted for up to 12 months for treatment of active systemic lupus erythematosus (SLE) in members 18 years or older when criteria are met.

Authorization period: up to 12 months

Note

Concomitant / Previous Therapy Requirement

Member must be receiving standard SLE therapy prior to initiating Saphnelo. Acceptable concomitant/previous therapies include glucocorticoids (e.g., prednisone, methylprednisolone, dexamethasone), antimalarials (e.g., hydroxychloroquine), or immunosuppressants (e.g., azathioprine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide).

Documentation Required

Required Documentation for Prior Authorization

Documentation required to initiate the prior authorization review: submit medical records (chart notes, laboratory reports) documenting presence of SLE-relevant autoantibodies prior to initiating therapy (examples: ANA by immunofluorescence [IFA] with titer ≥1:80, anti–double-stranded DNA [anti-dsDNA], anti-Smith [anti-Sm], antiphospholipid antibodies, or evidence of low complement proteins). For continuation requests, submit medical records (chart notes, lab reports) documenting disease stability or improvement.

Initial requests: medical records documenting autoantibodies relevant to SLE (e.g., ANA by IFA ≥1:80, anti-dsDNA, anti-Sm, antiphospholipid antibodies, low complement proteins).
Continuation requests: medical records documenting disease stability or improvement.

Denial Risk

Exclusion / Denial Risk

Denial risk: Coverage will not be provided for members with severe active lupus nephritis or severe active central nervous system (CNS) lupus when initiating Saphnelo. Also, Saphnelo in combination with other biologics is excluded.

Severe active lupus nephritis in a member initiating therapy — exclusion.
Severe active CNS lupus (including seizures attributed to CNS lupus, psychosis, organic brain syndrome, cerebritis, or CNS vasculitis requiring therapeutic intervention before initiation) in a member initiating therapy — exclusion.
Use of Saphnelo in combination with other biologics — exclusion.

Background

Saphnelo (anifrolumab) is an FDA‑approved biologic indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. The product has not been evaluated for, and is not recommended in, patients with severe active lupus nephritis or severe active central nervous system lupus.

Definitions

inv-12: Saphnelo (anifrolumab) definition

IndicationFDA‑approved biologic for treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy

PopulationAdults (age ≥18) with moderate to severe SLE

LimitationsNot evaluated for severe active lupus nephritis or severe active central nervous system lupus; use in these situations is not recommended